These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Elevated plasma concentration of neuropeptide Y in adolescents with primary hypertension. Lettgen B, Wagner S, Hänze J, Lang RE, Rascher W. J Hum Hypertens; 1994 May; 8(5):345-9. PubMed ID: 8064781 [Abstract] [Full Text] [Related]
4. Neuropeptide Y in neuroblastoma: increased concentration in metastasis, release during surgery, and characterization of plasma and tumor extracts. Kogner P, Björk O, Theodorsson E. Med Pediatr Oncol; 1993 May; 21(5):317-22. PubMed ID: 8492745 [Abstract] [Full Text] [Related]
5. Neuropeptide-Y and atrial natriuretic peptide as prognostic markers in patients on hemodialysis. Odar-Cederlöf I, Ericsson F, Theodorsson E, Kjellstrand CM. ASAIO J; 2003 May; 49(1):74-80. PubMed ID: 12558311 [Abstract] [Full Text] [Related]
8. Plasma neuropeptide Y of children with neuroblastoma in relation to stage, age and prognosis, and tissue neuropeptide Y. Dötsch J, Christiansen H, Hänze J, Lampert F, Rascher W. Regul Pept; 1998 Sep 25; 75-76():185-90. PubMed ID: 9802408 [Abstract] [Full Text] [Related]
10. Plasma catecholamines, neuropeptide Y and leucine-enkephalin in uremic patients before and after dialysis during rest and handgrip. Klin M, Waluga M, Rudka R, Madej A, Janiszewska M, Grzebieniak E, Wesolowky A. Boll Chim Farm; 1998 Sep 25; 137(8):306-13. PubMed ID: 9835145 [Abstract] [Full Text] [Related]
12. Is neuropeptide Y a contributor to volume-induced hypertension? Odar-Cederlöf I, Ericsson F, Theodorsson E, Kjellstrand CM. Am J Kidney Dis; 1998 May 25; 31(5):803-8. PubMed ID: 9590190 [Abstract] [Full Text] [Related]
13. Neuropeptide Y receptor Y2 gene polymorphism interacts with plasma neuropeptide Y levels in predicting left ventricular hypertrophy in dialysis patients. Testa A, Mallamaci F, Macrì R, Pisano A, Spoto B, Malatino LS, Stancanelli B, Tripepi G, Benedetto FA, Zoccali C. J Hypertens; 2010 Aug 25; 28(8):1745-51. PubMed ID: 20543711 [Abstract] [Full Text] [Related]
14. Elevated plasma immunoreactive neuropeptide Y concentrations and its increased urinary excretion in patients with advanced diabetic nephropathy. Satoh C, Satoh F, Takahashi K, Murakami O, Sone M, Totsune K, Yabe T, Ohneda M, Fukuda M, Sugimura K, Ogawa S, Nagakubo H, Sato T, Mouri T. Endocr J; 1999 Feb 25; 46(1):139-46. PubMed ID: 10426578 [Abstract] [Full Text] [Related]
16. Plasma neuropeptide Y (NPY) and galanin before and during exercise in type 1 diabetic patients with autonomic dysfunction. Sundkvist G, Bramnert M, Bergström B, Manhem P, Lilja B, Ahrén B. Diabetes Res Clin Pract; 1992 Mar 25; 15(3):219-26. PubMed ID: 1374311 [Abstract] [Full Text] [Related]
17. Renal and systemic plasma immunoreactive neuropeptide Y and calcitonin gene-related peptide responses to mental stress and adrenaline in humans. Tidgren B, Theodorsson E, Hjemdahl P. Clin Physiol; 1991 Jan 25; 11(1):9-19. PubMed ID: 2019081 [Abstract] [Full Text] [Related]
18. Neuropeptide Y, noradrenaline and invasive haemodynamic data in mild to moderate chronic congestive heart failure. Ullman B, Jensen-Urstad M, Hulting J, Lundberg JM. Clin Physiol; 1993 Jul 25; 13(4):409-18. PubMed ID: 8370239 [Abstract] [Full Text] [Related]
19. Circulating neuropeptide Y in plasma from uremic patients consists of multiple peptide fragments. Hegbrant J, Thysell H, Ekman R. Peptides; 1995 Jul 25; 16(3):395-7. PubMed ID: 7651890 [Abstract] [Full Text] [Related]
20. Neuropeptide Y and chronic kidney disease progression: a cohort study. Zoccali C, D'Arrigo G, Leonardis D, Pizzini P, Postorino M, Tripepi G, Mallamaci F, van den Brand J, van Zuilen A, Wetzels J, Bots ML, Blankestijn P. Nephrol Dial Transplant; 2018 Oct 01; 33(10):1805-1812. PubMed ID: 29370406 [Abstract] [Full Text] [Related] Page: [Next] [New Search]